What was studied?
GLORY-1 randomized 610 adults in China to mazdutide or placebo for 48 weeks. The two primary weight endpoints were evaluated at week 32.
What did the researchers report?
Both mazdutide groups showed greater average weight reduction than placebo at the primary assessment, with further results reported at week 48. Gastrointestinal events were the most frequent adverse effects.
What are the limits?
Eligibility used the study's BMI thresholds and related conditions. These results should not be generalized without considering population differences, and the paper does not certify research-supply product quality or clinical suitability.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.